Audrey Sternberg

Pelcitoclax/Osimertinib Combo Shows Preliminary Effiacy in EGFR+ NSCLC

September 8th 2021

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

Mobocertinib Shows Superior PROs in Previously Treated EGFR Exon 20+ Metastatic NSCLC

September 8th 2021

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

Brexucabtagene Autoleucel Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4

June 13th 2021

Daratumumab Maintenance Prolongs Responses Following ASCT and Standard Consolidation/Induction in Myeloma

June 12th 2021

Daratumumab maintenance therapy yielded an increase in response following autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

June 11th 2021

Intensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell transplant yielded robust responses in patients with ultra¬ high–risk multiple myeloma or primary plasma cell leukemia

Subsequent Therapy May Impact OS Outcomes With Frontline Lenvatinib/Everolimus in RCC

June 8th 2021

Subsequent systemic therapies were found to impact overall survival outcomes with lenvatinib plus everolimus versus sunitinib in patients with advanced renal cell carcinoma who received treatment in the phase 3 CLEAR trial.

HRQOL Analysis Further Supports Pembrolizumab/Lenvatinib for Frontline RCC

June 7th 2021

Frontline treatment with the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma led to similar health-related quality of life outcomes and disease-related symptom scores vs sunitinib.

Nivolumab/Ipilimumab Plus Chemotherapy Shows Durable Benefit in Advanced NSCLC

June 4th 2021

Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.

Screening, Vaccination Guidance May Be Responsible for Decline in HPV-Related Cervical Cancer

May 19th 2021

Evidence from a population-based study on the incidence of human papillomavirus–related cancers indicate a marked decline in cervical carcinoma, potentially due to clear guidance regarding screening measures and HPV vaccination for vulnerable patient groups.

Atezolizumab Induces Durable Activity Irrespective of MSI Status in Advanced Solid Tumors With TMB ≥16 Mut/Mb

April 13th 2021

Atezolizumab elicited durable clinical activity irrespective of microsatellite instability status in patients with advanced solid tumors with a tumor mutational burden of more than 16 mutations per megabase.

Multi-Omics Approach to Personalized Therapy Shows Feasibility in Metastatic Breast Cancer

April 13th 2021

A multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data has demonstrated feasibility in patients metastatic breast cancer vs DNA sequencing alone.

Lenvatinib Plus Everolimus Safe, Effective Following Immunotherapy in Clear Cell RCC

February 11th 2021

February 11, 2021 - Lenvatinib in combination with everolimus has proven to be safe and effective when used in the treatment of patients with clear cell renal cell carcinoma who had previously received an immune checkpoint inhibitor.

CPX-351 Continues to Improve OS in High-Risk AML Subtypes

February 10th 2021

February 10, 2021 - CPX-351 demonstrated improved overall survival at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Amivantamab Shows Encouraging Activity in EGFR Exon 20–Positive NSCLC

January 29th 2021

January 29, 2021 - Amivantamab elicited high and sustained responses in pretreated patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Pembrolizumab/Chemo Demonstrates Continued OS Improvement in Nonsquamous NSCLC

January 28th 2021

January 28, 2021 — Pembrolizumab in combination with chemotherapy continued to show improved overall survival and progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic nonsquamous non–small cell lung cancer.

Pembrolizumab Induces Antitumor Activity in Previously Untreated HCC

January 18th 2021

Single-agent pembrolizumab demonstrated durable antitumor activity among patients with treatment-naïve hepatocellular carcinoma, suggesting that the checkpoint inhibitor may have additional utility in this space, according to findings from a phase 2 trial presented during the 2021 Gastrointestinal Cancers Symposium.

Efficacy Analysis for Frontline Combination Therapy With Pembrolizumab Indicates Benefit in TNBC, Regardless of Chemotherapy Choice

December 10th 2020

December 10, 2020 - Frontline pembrolizumab plus chemotherapy for advanced triple-negative breast cancer demonstrated efficacy across key patient subgroups, including those with PD-L1 expression by combined positive score.

Tumor Subtype Can Be a Prognostic Marker for Patients Treated with Ribociclib

December 9th 2020

December 9, 2020 - Intrinsic tumor subtype was found to be associated with prognosis in patients with hormone receptor–positive, HER2-negative advance breast cancer who received the CDK4/6 inhibitor ribociclib.

Promising Data From Selinexor Plus Pd in Myeloma Spur Combo to Phase 3 Trial

December 8th 2020

Results reported from a group of patients with heavily pretreated multiple myeloma who were administered the combination of selinexor plus pomalidomide and low-dose dexamethasone produced positive responses and provided rationale for further investigation into the regimen.

Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel

December 5th 2020

December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.